Let there be light: On the 2026 Nobel Prize in Physiology/Medicine

The Nobel Prizes are announced every year in early October, traditionally beginning with the Prize in Physiology or Medicine, followed by Physics, Chemistry, Literature, Peace, and Economic Sciences. Instituted in 1901 pursuant to the 1895 will of Swedish industrialist Alfred Nobel, these prizes honour milestones that generate profound societal and scientific impact.

The 2026 Nobel Prize in Physiology or Medicine recognised American neuroscientist Karl Deisseroth alongside German biophysicists Peter Hegemann and Georg Nagel. Their joint discoveries enabled the birth of optogenetics, a revolutionary discipline where light-sensitive proteins called channelrhodopsins are introduced into specific neurons, allowing researchers to activate or silence them with millisecond precision.

In his last will signed in Paris in 1895, Swedish industrialist Alfred Nobel bequeathed the majority of his wealth to fund annual prizes. He explicitly instructed that the prize in Physiology or Medicine honour those who “conferred the greatest benefit to humankind”, establishing a global benchmark for discoveries that alter human welfare.

The human brain contains approximately 86 billion neurons that communicate through electrical signals and chemical messengers across junctions called synapses. Prior to optogenetics, scientists lacked tools to selectively stimulate individual circuits without disturbing surrounding brain areas, severely limiting our understanding of how distinct neural pathways regulate memory, emotion, and behavior.

Brain mapping refers to charting the spatial anatomy and functional connections across neural networks. International endeavours, such as the U.S. BRAIN Initiative launched in 2013, rely on optogenetic tools to identify and manipulate specific cell types, constructing comprehensive functional maps of how circuits process sensory signals and govern complex behaviour.

Scientific discoveries celebrated by the Nobel Committee often rely on cross-border cooperation. Optogenetics emerged through foundational biophysical discoveries made at the Max Planck Institute in Germany, which were subsequently synthesized with bioengineering methods at Stanford University in the United States.

In 2002 and 2003, German researchers Peter Hegemann and Georg Nagel discovered that the green alga Chlamydomonas reinhardtii senses light using proteins named Channelrhodopsin-1 and Channelrhodopsin-2. Unlike human eye photoreceptors that depend on complex multi-step chemical cascades, channelrhodopsin functions as a self-contained channel that opens instantly in response to blue light, allowing positive ions to stream inside and generate an immediate electrical voltage.

In 2005, bioengineer Karl Deisseroth and his team at Stanford University successfully inserted the gene encoding algal channelrhodopsin into mammalian neurons using harmless viral carriers. When hit by brief flashes of blue light, these engineered neurons fired electrical impulses on command, demonstrating that mammalian brain circuits could be activated and studied with millisecond precision.

In optogenetics, scientists employ modified adeno-associated viruses (AAVs) from which disease-causing viral sequences have been removed. These engineered vectors act as harmless biological delivery trucks, ferrying the genetic blueprints of algal light-sensitive proteins directly into targeted neuronal populations.

Over the past two decades, optogenetic experiments in laboratory models have successfully decoded neural pathways underpinning fear conditioning, depression, social interaction, and obsessive-compulsive behaviours. By selectively switching on and off specific dopaminergic or GABAergic circuits, neuroscientists have linked discrete cellular networks directly to complex mental states.

In Alzheimer’s disease research, optogenetic stimulation of gamma brainwave rhythms has been shown to activate brain immune cells (microglia) to clear neurotoxic amyloid plaques in laboratory models. Similarly, in substance abuse research, optogenetic techniques allow scientists to precisely dampen compulsive drug-seeking pathways, paving the way for next-generation deep-brain stimulation implants.

In degenerative diseases such as retinitis pigmentosa, the eye’s light-sensing photoreceptor cells die, but underlying retinal ganglion cells remain viable. By delivering genes for channelrhodopsin directly into these surviving cells via viral injections, researchers transform them into functional light sensors, successfully restoring partial vision and object recognition in clinical trials.

Translational medicine describes the “bench-to-bedside” trajectory of converting molecular discoveries from laboratories into clinical treatments. International organizations such as the World Health Organization (WHO) consistently emphasize that advanced genetic and neurobiological treatments must not remain restricted to wealthy nations, calling on governments to implement equitable access policies so that medical innovations benefit all socioeconomic strata.